Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms

被引:1
|
作者
Zhang, Yuhui [1 ]
Han, Yingdi [1 ]
Teng, Guangshuai [1 ]
Du, Chenxiao [1 ]
Gao, Shan [1 ]
Yuan, Weiping [2 ]
Zhang, Lei [2 ]
Bai, Jie [1 ]
机构
[1] Second Hosp Tianjin Med Univ, Dept Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 08期
基金
中国国家自然科学基金;
关键词
clinical characteristics; myeloproliferative neoplasms; risk factors; secondary cancer; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; ADULT PATIENTS; SOLID TUMORS; CANCER; TRANSFORMATION; SURVIVAL;
D O I
10.1002/cam4.5666
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe clinical characteristics and survival of patients with myeloproliferative neoplasms (MPNs) with secondary cancer were analyzed to explore the possible risk factors for secondary cancer in MPN patients. MethodsThe clinical characteristics of 1060 Chinese patients with MPN were retrospectively analyzed. The Kaplan-Meier method was used to analyze the survival. The Cox multivariate regression model was used to analyze the risk factors for developing secondary cancer in patients with MPNs. ResultsThe 1060 patients with MPN had a median follow-up of 10 years (range 1-50) and a median age of 55 years (range 21-86), and 497 (45.2%) were male. The proportion of PV, ET, and PMF was 52.2%, 33.5%, and 14.3%, respectively. About 28.1% (298/1060) of 1060 MPN patients died. The median survival times of the PV, ET, and PMF groups were 20, 24, and 12 years, respectively (p < 0.0001). In age- and sex-matched healthy Chinese patients, the standardized incidence ratio (SIR) value of developing secondary cancer in MPN patients was 6.41 (95% CI: 4.90-9.48). The median survival time was 14 years in the MPN with secondary cancer group. The Cox multivariate analysis showed that age >= 65 years (p < 0.0001, HR = 5.027, 95% CI [2.823, 8.952]), MF-1 (p = 0.001, HR = 2.887, 95% CI [1.503, 5.545]) were risk factors for developing secondary cancer. ConclusionsThe survival of MPN patients with secondary cancer was significantly worse than that of patients without secondary cancer. Compared with normal subjects, MPN patients had a 6.41-fold increased risk of developing secondary cancer, and age >= 65 years and MF-1 were risk factors for developing secondary cancer in MPN patients.
引用
收藏
页码:9236 / 9246
页数:11
相关论文
共 50 条
  • [31] Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms
    Vianello, Fabrizio
    Battisti, Anna
    Cella, Giuseppe
    Marchetti, Marina
    Falanga, Anna
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 1131 - 1137
  • [32] Incidence of second malignancies among pediatric patients treated with helical Tomotherapy
    Coassin, E.
    Drigo, A.
    Barresi, L.
    Fanetti, G.
    Elia, C.
    Sartor, G.
    Franchin, G.
    Mascarin, M.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S870 - S870
  • [33] Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib
    Ritchie, Ellen K.
    Krichevsky, Spencer
    Roboz, Gail J.
    Silver, Richard T.
    Schafer, Andrew I.
    Scandura, Joseph
    Desai, Pinkal
    Samuel, Sangmin Leeand Michael
    BLOOD, 2017, 130
  • [34] Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms Single-center Experience
    Kissova, Jarmila
    Ovesna, Petra
    Penka, Miroslav
    Bulikova, Alena
    Kiss, Igor
    ANTICANCER RESEARCH, 2014, 34 (05) : 2489 - 2496
  • [35] Second malignancies in Philadelphia-positive and -negative myeloproliferative neoplasms: A single center study
    Solmaz, Soner
    Korur, Asli
    Gereklioglu, Cigdem
    Asma, Suheyl
    Buyukkurt, Nurhilal
    Kasar, Mutlu
    Yeral, Mahmut
    Kozanoglu, Ilknur
    Boga, Can
    Ozdogu, Hakan
    EUROPEAN JOURNAL OF THERAPEUTICS, 2016, 22 (02): : 72 - 75
  • [36] Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms
    Hansen, Iben Onsberg
    Sorensen, Anders Lindholm
    Hasselbalch, Hans Carl
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (01) : 75 - 84
  • [37] Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
    Kim, Jinyong
    Byun, Ja Min
    Hong, Junshik
    Koh, Youngil
    Shin, Dong-Yeop
    Kim, Inho
    Yoon, Sung-Soo
    Park, Hyunkyung
    Bang, Soo-Mee
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [38] Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
    Jinyong Kim
    Ja Min Byun
    Junshik Hong
    Youngil Koh
    Dong-Yeop Shin
    Inho Kim
    Sung-Soo Yoon
    Hyunkyung Park
    Soo-Mee Bang
    Scientific Reports, 11
  • [39] Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications
    Brabrand, Mette
    Frederiksen, Henrik
    CANCERS, 2020, 12 (10) : 1 - 18
  • [40] Risk for Second Primary Malignancies Among Breast Cancer Patients
    Yi, M.
    Smith, B.
    Mittendorf, E. A.
    Black, D. M.
    McNeill, L. H.
    Bevers, T. B.
    Hunt, K. K.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S53 - S53